{"schema_version":"secwatch.filing_event.v1","accession":"0000874501-25-000084","form_type":"8-K","ticker":"OSG","cik":"0000874501","company_name":"OCTAVE SPECIALTY GROUP INC","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.539035+00:00","generated_at":"2026-05-22T01:03:18.312559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ambac Q1 revenue up 27% to $63M but net loss widens; adjusted EBITDA negative","bullets":["Total P&C premium production up 70% to $318M; revenue from continuing ops $63M (+27% YoY).","Net loss from continuing ops attributable to shareholders of $16.1M vs $4.1M loss in Q1'24.","Diluted EPS from continuing ops loss of $1.22 vs prior year EPS of $0.44 gain.","Adjusted EBITDA to shareholders negative $1.3M vs positive $0.4M; Cirrata segment adjusted EBITDA up 136%.","Legacy business sale pending only Wisconsin regulatory approval; discontinued ops net loss of $30.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000874501-25-000084","json":"https://secwatch.observer/filing/0000874501-25-000084.json","markdown":"https://secwatch.observer/filing/0000874501-25-000084.md","text":"https://secwatch.observer/filing/0000874501-25-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874501/000087450125000084/0000874501-25-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874501/000087450125000084/ambc-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:03:18.312559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}